

# SWISS INSTITUTE OF CELL THERAPIES

From engineering innovation to clinical translation

**WEDNESDAY, 11 NOVEMBER 2026**

**13:00-18:00**

## LAUSANNE UNIVERSITY HOSPITAL (CHUV)

Lausanne, Switzerland | Welcome coffee and closing aperitif

**ORGANIZATION** Yannick Muller (Service d'immunologie et allergie) | Francesco Ceppi (Service de pédiatrie)

### 1 ACTIVE CELL THERAPY PROGRAMS AT CHUV

**Anthony de Buys Roessingh** (CHUV, Lausanne)

Skin Replacement Program at the Centre romand des brûlés

**Bernhard Gentner** (CHUV, Lausanne)

TILs and NY-ESO-1 T-Cell Therapy Programs

**Caroline Arber** (CHUV, Lausanne)

Anti-CD70 CAR T-Cell Program

### 2 EMERGING CELL-ENGINEERING TECHNOLOGIES

**Brian Shy** (UCSF, San Francisco)

Non-Viral Gene Editing and Large-Fragment Knock-In under GMP-Compatible Conditions

**Melita Irving** (UNIL, Lausanne)

RNA Interference and Safety Switches: An All-in-One Vector Platform

### 3 CELL THERAPY FOR AUTOIMMUNE DISEASES

**Fabrizio De Benedetti** (Bambino Gesù Children's Hospital IRCCS, Rome)

CD19 CAR T-Cell Therapy for Pediatric Autoimmune Diseases

**Rafael Correia** (Instituto de Investigación Sanitaria Gregorio Marañón, Madrid)

Thymus-Derived Regulatory T Cell Therapy: A New Platform for Immune Tolerance

### ROUND-TABLE DISCUSSION

The future of academic cell therapy and clinical translation